Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pluripotency-independent induction of human trophoblast stem cells from fibroblasts.
Naama M, Rahamim M, Zayat V, Sebban S, Radwan A, Orzech D, Lasry R, Ifrah A, Jaber M, Sabag O, Yassen H, Khatib A, Epsztejn-Litman S, Novoselsky-Persky M, Makedonski K, Deri N, Goldman-Wohl D, Cedar H, Yagel S, Eiges R, Buganim Y. Naama M, et al. Among authors: deri n. Nat Commun. 2023 Jun 8;14(1):3359. doi: 10.1038/s41467-023-39104-1. Nat Commun. 2023. PMID: 37291192 Free PMC article.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study.
Silva BA, Miglietta E, Casabona JC, Wenker S, Eizaguirre MB, Alonso R, Casas M, Lázaro LG, Man F, Portuondo G, Lopez Bisso A, Zavala N, Casales F, Imhoff G, Steinberg DJ, López PA, Carnero Contentti E, Deri N, Sinay V, Hryb J, Chiganer E, Leguizamon F, Tkachuk V, Bauer J, Ferrandina F, Giachello S, Henestroza P, Garcea O, Pascuale CA, Heitrich M, Podhajcer OL, Vinzón S, D'Alotto-Moreno T, Benatar A, Rabinovich GA, Pitossi FJ, Ferrari CC. Silva BA, et al. Among authors: deri n. Front Immunol. 2024 Aug 19;15:1431403. doi: 10.3389/fimmu.2024.1431403. eCollection 2024. Front Immunol. 2024. PMID: 39224589 Free PMC article.
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.
De Brouwer E, Becker T, Werthen-Brabants L, Dewulf P, Iliadis D, Dekeyser C, Laureys G, Van Wijmeersch B, Popescu V, Dhaene T, Deschrijver D, Waegeman W, De Baets B, Stock M, Horakova D, Patti F, Izquierdo G, Eichau S, Girard M, Prat A, Lugaresi A, Grammond P, Kalincik T, Alroughani R, Grand'Maison F, Skibina O, Terzi M, Lechner-Scott J, Gerlach O, Khoury SJ, Cartechini E, Van Pesch V, Sà MJ, Weinstock-Guttman B, Blanco Y, Ampapa R, Spitaleri D, Solaro C, Maimone D, Soysal A, Iuliano G, Gouider R, Castillo-Triviño T, Sánchez-Menoyo JL, Laureys G, van der Walt A, Oh J, Aguera-Morales E, Altintas A, Al-Asmi A, de Gans K, Fragoso Y, Csepany T, Hodgkinson S, Deri N, Al-Harbi T, Taylor B, Gray O, Lalive P, Rozsa C, McGuigan C, Kermode A, Sempere AP, Mihaela S, Simo M, Hardy T, Decoo D, Hughes S, Grigoriadis N, Sas A, Vella N, Moreau Y, Peeters L. De Brouwer E, et al. Among authors: deri n. PLOS Digit Health. 2024 Jul 25;3(7):e0000533. doi: 10.1371/journal.pdig.0000533. eCollection 2024 Jul. PLOS Digit Health. 2024. PMID: 39052668 Free PMC article.
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM).
Carnero Contentti E, Lopez PA, Patrucco L, Cristiano E, Miguez J, Silva B, Liwacki S, Tkachuk V, Balbuena ME, Vrech C, Deri N, Correale J, Marrodan M, Ysrraelit MC, Fiol M, Leguizamon F, Luetic G, Tavolini D, Mainella C, Zanga G, Burgos M, Hryb J, Barboza A, Lazaro L, Alonso R, Fernández Liguori N, Nadur D, Martinez A, Steinberg J, Carrá A, Alonso Serena M, Rojas JI. Carnero Contentti E, et al. Among authors: deri n. Mult Scler Relat Disord. 2024 Sep;89:105771. doi: 10.1016/j.msard.2024.105771. Epub 2024 Jul 20. Mult Scler Relat Disord. 2024. PMID: 39033591
Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina.
Rojas JI, Alonso R, Luetic G, Patrucco L, Casas M, Silva B, Miguez J, Deri N, Vrech C, Liwacki S, Piedrabuena R, Silva E, Tkachuk V, Burgos M, Tavolini D, Zanga G, Pinheiro AA, Hryb J, Leguizamon F, Knorre E, Lopez PA, Martinez A, Carrá A, Alonso Serena M, Cristiano E, Correale J, Garcea O, Fernandez Liguori N, Carnero Contentti E. Rojas JI, et al. Among authors: deri n. Clin Neuropharmacol. 2024 Jul-Aug 01;47(4):120-127. doi: 10.1097/WNF.0000000000000598. Epub 2024 May 22. Clin Neuropharmacol. 2024. PMID: 39008542
Treatment strategies and responses for attacks of neuromyelitis optica spectrum disorder: A real-world retrospective cohort study.
Carnero Contentti E, Lopez PA, Pettinicchi JP, Miguez J, Patrucco L, Cristiano E, Liwacki S, Tkachuk V, Balbuena ME, Vrech C, Deri N, Correale J, Marrodan M, Ysrraelit MC, Leguizamon F, Luetic G, Tavolini D, Mainella C, Zanga G, Burgos M, Hryb J, Barboza A, Lazaro L, Alonso R, Fernández Liguori N, Nadur D, Alonso Serena M, Caride A, Rojas JI. Carnero Contentti E, et al. Among authors: deri n. J Neurol Sci. 2024 Jul 15;462:123099. doi: 10.1016/j.jns.2024.123099. Epub 2024 Jun 14. J Neurol Sci. 2024. PMID: 38897155
89 results